Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2295 • ACR Convergence 2023
Predictors of Adherence to Cervical Cancer Screening Guidelines Among Patients with Systemic Lupus Erythematosus
Lindsay Cho and Alexandra Legge, Dalhousie University, Halifax, NS, Canada
Background/Purpose: Women with systemic lupus erythematous (SLE) are at increased risk for cervical dysplasia and cervical cancer. In our jurisdiction, current guidelines recommend that average-risk…
Abstract Number: 2311 • ACR Convergence 2023
Effect on Lupus Outcomes of the Protective Allele at rs1876453 in the Complement Receptor 2 Gene
Ani Oganesyan¹, Rachel Sharp², Philip O’Neill³, Cynthia Aranow⁴, Laurent Arnaud⁵, Anca Askanase⁶, Sang-Cheol Bae⁷, Sasha Bernatsky⁸, Ian Bruce⁹, Jill Buyon¹⁰, Winn Chatham¹¹, Ann Clarke¹², Nathalie Costedoat-Chalumeau¹³, Mary Anne Dooley¹⁴, Paul R. Fortin¹⁵, Ellen Ginzler¹⁶, Dafna Gladman¹⁷, Caroline Gordon¹⁸, John G. Hanly¹⁹, Murat Inanç²⁰, David Isenberg²¹, Soren Jacobsen²², Andreas Jonsen²³, Kenneth Kalunian²⁴, Diane L. Kamen²⁵, S. Sam Lim²⁶, Anselm Mak²⁷, Eric Morand²⁸, Christine Peschken²⁹, Michelle Petri³⁰, Bernando A. Pons-Estel³¹, Anisur Rahman³², Rosalind Ramsey-Goldman³³, John Reynolds³⁴, Juanita Romero-Diaz³⁵, Guillermo Ruiz-Irastorza³⁶, Jorge Sanchez-Guerrero³⁷, Kristjan Steinsson³⁸, Murray Urowitz³⁹, Ronald van Vollenhoven⁴⁰, Evelyne Vinet⁴¹, Alexandre Voskuyl⁴², Daniel Wallace⁴³, Susan Manzi⁴⁴, Kenneth L. Jones⁴⁵ and Susan A. Boackle⁴⁶, ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Feinstein Institutes for Medical Research, Manhasset, NY, ⁵University Hospitals of Strasbourg, Strasbourg, France, ⁶Columbia University Medical Center, New York, NY, ⁷Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology Research, Department of Rheumatology, Seoul, South Korea, ⁸Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁹University of Manchester, Manchester, United Kingdom, ¹⁰NYU Grossman School of Medicine, New York, NY, ¹¹University of Alabama at Birmingham, Birmingham, AL, ¹²University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, ¹³Inserm DR Paris 5, Paris, France, ¹⁴Raleigh Neurology Associates, Chapel Hill, NC, ¹⁵Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ¹⁶SUNY Downstate Health Sciences University, Brooklyn, NY, ¹⁷Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ¹⁸Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ¹⁹Dalhousie University, Halifax, NS, Canada, ²⁰Istanbul University, Istanbul, Turkey, ²¹University College London, London, United Kingdom, ²²Rigshospitalet, Copenhagen, Denmark, ²³Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden, ²⁴University of California San Diego, La Jolla, CA, ²⁵Medical University of South Carolina, Charleston, SC, ²⁶Emory University, Atlanta, GA, ²⁷Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ²⁸Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ²⁹University of Manitoba, Winnipeg, MB, Canada, ³⁰Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ³¹Study Group of the Argentine Society of Rheumatology for Systemic Lupus Erythematosus, Buenos Aires, Argentina, ³²Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ³³Northwestern University, Chicago, IL, ³⁴University of Birmingham, Birmingham, United Kingdom, ³⁵Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ³⁶Hospital Universitario Cruces, Barakaldo, Spain, ³⁷University Health Network, Toronto, ON, Canada, ³⁸Landspitali University Hospital, Reykjavik, Iceland, ³⁹Schroeder Arthritis Institute, Krembil Research Institute; University of Toronto Lupus Clinic; Division of Rheumatology, Toronto, ON, Canada, ⁴⁰Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁴¹McGill University Health Centre, Montréal, QC, Canada, ⁴²Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ⁴³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴⁴Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ⁴⁵Bioinformatics Solutions, Sheridan, WY, ⁴⁶None, Denver, CO
Background/Purpose: Systemic lupus erythematosus is a heterogenous autoimmune disease characterized by inflammatory damage to multiple organ systems. We have shown that the single-nucleotide polymorphism (SNP)…
Abstract Number: 2327 • ACR Convergence 2023
Hydroxychloroquine Improves Low Complement Levels
Michelle Petri¹, Rebecca Jacobson², Andrea Fava³ and Larry Magder⁴, ¹Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD, ⁴University of Maryland, Baltimore, MD
Background/Purpose: Low complement is associated with clinical disease activity and future organ damage in patients with systemic lupus erythematosus (SLE). Prior studies from Japan, although…
Abstract Number: 2347 • ACR Convergence 2023
Efficacy of Belimumab in Patients with Systemic Lupus Erythematosus by Race and Ethnicity: A Large Post Hoc Integrated Analysis of Five Clinical Trials
Saira Sheikh¹, Amit Saxena², Angela Carroll³, Christine Henning³, Julia HN Harris⁴, Bernard Rubin⁵, David D'Cruz⁶ and Alvin F Wells⁷, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²New York University Grossman School of Medicine, Rheumatology, New York, NY, ³GlaxoSmithKline, US Medical Affairs, Durham, NC, ⁴GlaxoSmithKline, Immunology Biostatistics, Brentford, United Kingdom, ⁵GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC, ⁶Guy’s Hospital, Louise Coote Lupus Unit, London, United Kingdom, ⁷Advocate Health Department of Rheumatology, Franklin, WI
Background/Purpose: Belimumab (BEL) is approved for the treatment of active SLE, and lupus nephritis, with standard therapy.1 The prevalence and severity of SLE tend to…
Abstract Number: 2460 • ACR Convergence 2023
Health Care Segregation, but Not Metropolitan Area Segregation, Magnifies Racial Disparities in Hospital Outcomes of Pediatric Lupus
Joyce Chang¹, Jessica Liu¹, Laura Berbert¹, Edie Weller¹, Gabrielle Alonzi¹, Emily Smitherman², Pooja Patel³, Mary Beth Son⁴ and Karen Costenbader⁵, ¹Boston Children's Hospital, Boston, MA, ²University of Alabama at Birmingham, Birmingham, AL, ³Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁴Division of Immunology, Boston Children's Hospital, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Racial disparities and hospital-level variation in pediatric SLE (pSLE) outcomes are well described, but it is not known how the racial and ethnic composition…
Abstract Number: 2553 • ACR Convergence 2023
Prevalence, Determinants and Outcomes of Target Attainment in SLE Patients with Clinically Active Disease in a Large Multinational Prospective Lupus Cohort
Yanjie Hao¹, Dylan Hansen², Rangi Kandane-Rathnayake³, Worawit Louthrenoo⁴, Yi-Hsing Chen⁵, Jiacai Cho⁶, Aisha Lateef⁶, Laniyati Hamijoyo⁷, Shue-Fen Luo⁸, Yeong-Jian J Wu⁹, Sandra Navarra¹⁰, Leonid Zamora¹⁰, Zhanguo Li¹¹, Sargunan Sockalingam¹², Yasuhiro Katsumata¹³, Masayoshi Harigai¹³, Zhuoli Zhang¹⁴, Madelynn Chan¹⁵, Jun Kikuchi¹⁶, Tsutomu Takeuchi¹⁷, Sang-Cheol Bae¹⁸, Fiona Goldblatt¹⁹, Sean O’Neill²⁰, Kristine Ng²¹, Annie Law²², BMDB Basnayake²³, Nicola Tugnet²⁴, Sunil Kumar²⁵, Cherica Tee²⁶, Michael Tee²⁶, Yoshiya Tanaka²⁷, Chak Sing Lau²⁸, Vera Golder³, Alberta Hoi²⁹, Eric Morand³⁰, Shereen Oon³¹ and Mandana Nikpour³², ¹The University of Melbourne Department of Medicine at St Vincents Hospital Melbourne, Melbourne, Australia, ²Department of Rheumatology, St Vincent’s Hospital Melbourne, Fitzroy, Australia, ³Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Clayton, Australia, ⁴Chiang Mai University Hospital, Department of Internal Medicine, Faculty of Medicine, Chiang Mai, Thailand, ⁵Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, ⁶National University Hospital, Rheumatology Division, Department of Medicine, Singapore, Singapore, ⁷Padjadjaran University/Hasan Sadikin General Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Bandung, Indonesia, ⁸Chang Gung University, Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁹Chang Gung University, Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Keelung, Taiwan, ¹⁰University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines, ¹¹Peking University Health Science Center, Department of Rheumatology and Immunology, People's Hospital, Beijing, China, ¹²University of Malaya, Department of Medicine, Faculty of Medicine Building, Kuala Lumpur, Malaysia, ¹³Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ¹⁴Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, ¹⁵Tan Tock Seng Hospital, Department of Rheumatology, Allergy & Immunology, Singapore, Singapore, ¹⁶Keio University School of Medicine, Tokyo, Japan, ¹⁷Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ¹⁸Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology Research, Department of Rheumatology, Seoul, South Korea, ¹⁹Royal Adelaide Hospital and Flinders Medical Centre, Adelaide, Australia, ²⁰Department of Medicine, University of New South Wales, Kensington, Australia, ²¹Waitemata DHB, Auckland, New Zealand, ²²Singapore General Hospital; Duke-NUS Medical School, Singapore, Singapore, ²³Division of Nephrology, Teaching Hospital Kandy, Adelaide, Australia, ²⁴Auckland District Health Board, Auckland, New Zealand, ²⁵Middlemore Hospital, Auckland, New Zealand, ²⁶University of the Philippines, Manila, Philippines, ²⁷University of Occupational and Environmental Health, Kitakyushu, Japan, ²⁸University of Hong Kong, Division of Rheumatology & Clinical Immunology, Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ²⁹Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Melbourne, Australia, ³⁰Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ³¹University of Melbourne at St Vincent’s Hospital, Departments of Rheumatology and Medicine, Fitzroy, Australia, ³²The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia
Background/Purpose: There is increasing interest in adopting the principle of treating to target (T2T) in systemic lupus erythematosus (SLE). Remission and low disease activity states…
Abstract Number: 0118 • ACR Convergence 2023
Physical Performance Among Individuals with Systemic Lupus Erythematosus in a Diverse Population-Based Cohort
Courtney Hoge¹, C. Barrett Bowling², Charmayne Dunlop-Thomas¹, Bradley Pearce¹, S. Sam Lim¹, Cristina Drenkard¹ and Laura Plantinga¹, ¹Emory University, Atlanta, GA, ²Duke University, Durham, NC
Background/Purpose: Physical performance is often not measured in clinical settings, despite its association with increased risk of disability, loss of independence, and mortality. Here, we…
Abstract Number: 0183 • ACR Convergence 2023
Barriers and Facilitators to Recruiting Underrepresented Participants for Clinical Trials: Insights from the Lupus Clinical Investigators Network (LuCIN)
Tessa Englund¹, Christine Lee², Julie Hsieh², Richardae Araojo², Julia Mariano¹, Emily McCormick³, Stacie Bell⁴, Albert Roy⁵ and Saira Sheikh¹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²U.S. Food and Drug Administration, Silver Spring, MD, ³Thurston Arthritis Research Center, Chapel Hill, NC, ⁴Lupus Therapeutics, Lakewood, CO, ⁵Lupus Research Alliance, New York, NY
Background/Purpose: Despite greater prevalence of lupus among diverse, racial and ethnic minority populations, marked gaps exist between populations affected by lupus and those enrolled in…
Abstract Number: 0462 • ACR Convergence 2023
Breastfeeding Intention in Systemic Lupus Erythematosus Patients
Susana Villamizar Pérez¹, Nicole Josianne Paris¹, Melissa Serna Góngora¹, Ariel Brener¹, Jerson Claros¹, Maria Pia Izaguirre Germain¹, Barbara Pérez Cepas², Marina Micelli³, Gabriel Sequeira¹ and Eduardo Mario Kerzberg¹, ¹Hospital Dr. JM Ramos Mejia, Ciudad Autonoma de Buenos Aires, Argentina, ²Hospital medico policial Churruca Visca, Ciudad Autonoma de Buenos Aires, Argentina, ³RELESSAR, CABA, Argentina
Background/Purpose: Breastfeeding in systemic lupus erythematosus (SLE) has received little attention and the limited data available suggest that women with SLE have lower breastfeeding rates…
Abstract Number: 0555 • ACR Convergence 2023
Evaluation and Management of the “False Positive” ANA and Undifferentiated Connective Tissue Disease Amongst Rheumatologists
Neha Gupta¹, Sarah Ford², Lane Scheiber², Tangada Rao² and Abhishek Nandan², ¹Virginia Commonwealth University Health Systems, Richmond, VA, ²Virginia Commonwealth University Health Systems; Veterans Affairs Medical Center, Richmond, VA
Background/Purpose: The management of a positive anti-nuclear antibody (ANA) is one of the most common consultations in rheumatology outpatient practice. The prevalence of a positive…
Abstract Number: 0572 • ACR Convergence 2023
Serum/ Urine Levels and Expression of CD163 in Lupus Nephritis
Erdem Gurel¹, Suzan Cinar², Ozge Hurdogan³, Yasemin Ozluk³, Isin Kilicaslan⁴, Sibel Varelci¹, Safak Mirioglu⁵, Yasemin Yalcinkaya⁶, Ahmet Gul⁶, Lale Ocal¹, Murat Inanc⁶ and Bahar Artim-Esen⁶, ¹Division of Rheumatology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey, ²Department of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey, ³Department of Pathology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey, ⁴Department of Pathology, Istanbul University Istanbul School of Medicine, Istanbıl, Turkey, ⁵Division of Nephrology, Bezmialem Vakif University School of Medicine, Istanbul, Turkey, ⁶Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
Background/Purpose: CD163 is a glycosylated membrane protein expressed in monocytes and macrophages that phagocytize the hemoglobin/haptoglobin complex. As a result of proinflammatory stimuli, CD163 is…
Abstract Number: 0590 • ACR Convergence 2023
Comparing Safety and Efficacy of Sodium-Glucose Co-Transporter 2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Systemic Lupus Erythematosus and Comorbid Type 2 Diabetes Mellitus
Jui-En Lo¹, Pin-Chia Huang², George Tsokos³, Vasileios Kyttaris⁴, Karen Costenbader⁵ and Kevin Sheng-Kai Ma², ¹Center for Global Health, Perelman School of Medicine, Philadelphia, PA, ²Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, ³Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁴BIDMC, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Sodium-glucose co-transporter 2 inhibitors (SGLT2i), originally approved as oral hypoglycemic agents for type 2 diabetes (T2D), have been shown to reduce progression to end-stage…
Abstract Number: 0723 • ACR Convergence 2023
Investigating the Effects and Molecular Mechanisms of TRAF5 on the Pathogenesis of SLE Associated Pulmonary Arterial Hypertension
Xiaoyue Deng¹, Junyan Qian¹, Ranran Wang², JIULIANG ZHAO³, Qian Wang⁴, Tianyi Yuan², MENGTAO LI¹ and Xiaofeng Zeng⁵, ¹Peking Union Medical College Hospital, Beijing, China, ²Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ³Beijing Union Medical College Hospital, Beijing, China, ⁴Peking Union Medical College, Beijing, China, ⁵Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: Pulmonary arterial hypertension (PAH) is a serious complication in SLE patients, with rapid progression and poor prognosis. In China, approximately 3% of the over…
Abstract Number: 0848 • ACR Convergence 2023
Performance of Serum MRP8/14, sCD14, IL-6 and Neutrophil CD64 in Isolation and in Combination for Differentiating Flare from Bacterial Infection in Febrile SLE Patients
Kishan Majithiya¹, Komal Singh¹, Pankti Mehta², Chengappa Kavadichanda³, seema Sharma¹, Able Lawrence¹ and Amita Aggarwal¹, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ²King George's Medical University, Mumbai, India, ³Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
Background/Purpose: Disease flare and infections are the major causes of fever in a patient with SLE. It is vital to differentiate between these two as…
Abstract Number: 0903 • ACR Convergence 2023
Effects of Hydroxychloroquine on Maternal Outcomes in Pregnant Patients with Systemic Lupus Erythematous
Yurilu Gonzalez¹ and Irene Tan², ¹Albert Einstein Medical Center, Wyncote, PA, ²Einstein Medical Center Philadelphia, Bala Cynwyd, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease, that affects women of childbearing age. SLE is a high-risk condition in pregnant patients due…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].